Compare
Rani Therapeutics Holdings, Inc. vs NRX Pharmaceuticals, Inc. vs Avenue Therapeutics, Inc. vs Northwest Biotherapeutics Inc
| Latest fiscal year | Rani Therapeutics Holdings, Inc. RANI | NRX Pharmaceuticals, Inc. NRXP | Avenue Therapeutics, Inc. ATXI | Northwest Biotherapeutics Inc NWBO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.63M | $1.45M | $1.40M | $1.38M |
| Revenue growth (YoY) | +58.9% | n/a | n/a | -0.3% |
| Gross margin | n/a | 65.1% (computed) | n/a | n/a |
| Operating margin | n/m | n/m | -219.6% | n/m |
| Net margin | n/m | n/m | -207.2% | n/m |
| Net income | -$40.95M | -$28.62M | -$2.91M | -$60.16M |
| EPS (Diluted) | -$0.45 | n/a | n/a | -$0.04 |
| Operating cash flow | -$18.71M | -$14.11M | -$1.83M | -$44.76M |
| Free cash flow | -$18.80M | n/a | n/a | -$46.27M |
| Cash & equivalents | $18.62M | $7.80M | $2.85M | $3.04M |
| Total assets | $58.62M | $12.96M | $2.93M | $81.29M |
| Total liabilities | $17.11M | $28.89M | $1.10M | $128.86M |
| Shareholders' equity | $33.01M | -$15.94M | $1.83M | -$60.28M |
| Return on year-end equity | -124.1% | n/a | -158.8% | n/a |
| Shares outstanding | n/a | 31.73M | 3.18M | 1.56B |
Revenue, most recent five fiscal years
| Fiscal year | Rani Therapeutics Holdings, Inc. | NRX Pharmaceuticals, Inc. | Avenue Therapeutics, Inc. | Northwest Biotherapeutics Inc |
|---|---|---|---|---|
| Latest | $1.63M Ended 2025-12-31 | $1.45M Ended 2025-12-31 | $1.40M Ended 2025-12-31 | $1.38M Ended 2025-12-31 |
| 1 year earlier | $1.03M Ended 2024-12-31 | $0 Ended 2024-12-31 | $0 Ended 2024-12-31 | $1.38M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a | $1.93M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | n/a | n/a | $1.68M Ended 2022-12-31 |
| 4 years earlier | $2.72M Ended 2021-12-31 | n/a | n/a | $1.00M Ended 2021-12-31 |